title: Short double-stranded RNA with immunostimulatory activity: sequence dependence.
abstract: Small interfering RNAs (siRNA) are able to activate the mammalian innate immune system depending on their structure, sequence, and method of delivery. The immunostimulatory activity of double-stranded RNA can be applied to antiviral and antitumor therapy. Here we identified a set of 19-bp RNA duplexes with 3-nucleotid overhangs in the 3' ends that display immunostimulating activity (here and after immunostimulating RNA, or isRNA) and studied their sequence/activity relationships. It was found that the introduction of substitutions in the middle part of the isRNA sequence (10-16 positions counting from the 5' end of strand 1) does not alter the antiproliferative activity, while substitutions in the 3' end region of isRNA substantially reduce it. isRNAs efficiently inhibit the proliferation of human oral epidermoid carcinoma cells [half-maximal inhibitory concentration (IC(50)) values varied from 10 to 100 nM]. Our research demonstrated that antiproliferative effects of isRNAs are related to cell growth arrest, rather than the induction of apoptosis. These isRNAs strongly stimulate the synthesis of interferon-α (IFN-α), and to a lesser extent the synthesis of tumor necrosis factor (TNF-α) and interleukin-6 (IL-6), in adherent peripheral blood mononuclear cells. An intravenous injection of isRNA/Lipofectamine complexes into C57BL mice increases IFN-α and IL-6 levels in the blood serum up to 15-fold and 3-fold, respectively, compared to the control mice. The results obtained clearly demonstrate the pronounced immunostimulatory and antiproliferative properties of the isRNAs under study. Hence, these short double-stranded RNAs can be considered as potential agents for the therapy of oncological and viral diseases.
authors.affiliation: Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Science, Novosibirsk, Russia.
authors.forename: Tatyana O
authors.initials: TO
authors.lastname: Kabilova
authors.forename: Mariya I
authors.initials: MI
authors.lastname: Meschaninova
authors.forename: Alya G
authors.initials: AG
authors.lastname: Venyaminova
authors.forename: Valery P
authors.initials: VP
authors.lastname: Nikolin
authors.forename: Marina A
authors.initials: MA
authors.lastname: Zenkova
authors.forename: Valentin V
authors.initials: VV
authors.lastname: Vlassov
authors.forename: Elena L
authors.initials: EL
authors.lastname: Chernolovskaya
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D001483:Base Sequence; D002294:Carcinoma, Squamous Cell / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D016207:Cytokines / Q000097:blood; D005434:Flow Cytometry; D006801:Humans; D020128:Inhibitory Concentration 50; D051379:Mice; D008810:Mice, Inbred C57BL; D009062:Mouth Neoplasms / Q000473:pathology; D012330:RNA, Double-Stranded / Q000502:physiology*; D034741:RNA, Small Interfering / Q000235:genetics
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D012330:RNA, Double-Stranded; D034741:RNA, Small Interfering